Lecture Details - Overview
Toward Curing Myeloma: Recent Data and Updated Clinical Strategies
Release Date: March 10, 2009|
Expiration Date: March 10, 2010
Mar 10, 2009, Expert Interviews
Lecture Overview
The 21st century has witnessed an upsurge in the development of novel targeted agents for multiple myeloma (MM). Proteasome inhibitors as treatment of relapsed/refractory disease were introduced into the clinic in 2003 and recently received approval by the US Food and Drug Administration (FDA) for use in the first-line treatment of patients with MM who are ineligible for transplantation. In 2006, immunomodulatory agents were approved by the FDA for the treatment of newly diagnosed or relapsed/refractory disease; together, these 2 drug classes have provided a shift in the treatment paradigm for MM, with complete response rates approaching those previously attainable only with autologous stem cell transplantation. Current development of immunomodulatory agents and proteasome inhibitors includes evaluation of these drugs as part of novel combinations of conventional and/or newer chemotherapies. Studies have begun to investigate multiple-agent regimens that incorporate different classes of targeted drugs. Second-generation agents are emerging, and with increased understanding of the biology of MM, newer targeted-agent classes are being evaluated for synergistic antimyeloma activity.
The purpose of this activity is to inform physicians about cutting-edge developments in targeted agents for the management of patients with newly diagnosed and relapsed/refractory MM.
This educational activity is intended for medical oncologists and hematologists involved in the care of patients with MM. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Upon completion of this educational activity, you should be able to:
- Assess the efficacy and safety of varying corticosteroid doses in combination with immunomodulatory agent–based induction therapy for newly diagnosed MM
- Discuss clinical approaches to enhancing proteasome inhibition in MM
- Describe the efficacy of combining immunomodulatory agents and proteasome inhibitors in relapsed/refractory MM
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- View and study the Flash video presentations and slides.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
- Return to this activity to view a list of questions and scenarios from your peers. This part of the activity is not available for CME credit.
- Return April 7, 2009, to access the answers to the questions.
- You will be permitted 2 attempts to successfully complete the Posttest.
Submit Your Questions/Scenarios and Be Part of the Expert Interview!
E-mail your specific clinical scenarios or questions on this topic to editor@cancerlearning.com with the subject title 8645, or fax them to (214) 367-3304 directed to 8645.
Return to this activity to view a list of questions and scenarios from your peers. Questions submitted by March 24, 2009, will be addressed in an on-demand online interview with an expert or answered directly by e-mail, as appropriate.
You will be asked to login
or create an account.